Jianxin X. Xue - Publications

Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.

Journal: Molecular cancer

Published: April 13, 2026

High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy.

Journal: International journal of cancer

Published: March 23, 2026

Yin-Huang-Qing-Fei-Capsule derived diosgenin and its optimized nanoconjugate target STAT3 against pulmonary fibrosis.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: March 16, 2026

Prognostic value of perioperative inflammatory biomarkers in patients undergoing surgical resection for non-small cell lung cancer.

Journal: Journal of thoracic disease

Published: March 13, 2026

Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming.

Journal: Signal transduction and targeted therapy

Published: February 13, 2026

Explainable machine learning integrating metabolic and inflammatory signatures for personalized prognosis in resected intrahepatic cholangiocarcinoma.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 30, 2026

Biomimetic Synthesis of Multinuclear Metal-Oxo Bridges Under Mild Aqueous Conditions for Catalytic Cancer Therapy.

Journal: Angewandte Chemie (International ed. in English)

Published: January 19, 2026

Multimodal deep learning for survival prediction and biomarker discovery in non-small cell lung cancer.

Journal: BioData mining

Published: November 06, 2025

Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification.

Journal: Materials today. Bio

Published: October 30, 2025

Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.

Journal: International journal of cancer

Published: October 20, 2025

Impact of Response Assessment Intervals on Survival and Economic Burden in Long-Term Responders to Immunotherapy for Advanced Non-Small-Cell Lung Cancer.

Journal: Cancers

Published: September 12, 2025

Drug allergy history predicts early progression-free survival benefit from PD-(L)1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 10, 2025